Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs. - Koopman LA; Alemdehy F; de Poot SAH; Paauwe M; Wang W; Epstein KR; van den Brink EN; Gorlani A; Verzijl D; Brandhorst M; Franken P; Smits-de Vries L; et al. (Molecular cancer therapeutics, 2026)